{"type":"trials","record":{"id":41818,"source_id":"clinicaltrials-gov","external_id":"NCT06899360","title":"Evaluation of Clinical Progression, Prognostic Factors, and Quality of Life in Patients with Age-related Macular Degeneration.","brief_summary":"The VERA-AMD study is a prospective, observational study designed to evaluate clinical progression, prognostic factors, and quality of life in patients with age-related macular degeneration (AMD). The study aims to analyze real-world clinical data to identify key predictors of disease progression and functional outcomes, with the goal of optimizing AMD management. The study involves 200 patients aged ≥50 with a confirmed diagnosis of AMD, monitored through routine clinical practice. Primary outcomes include progression rates to advanced AMD and changes in visual acuity, while secondary outcomes focus on retinal morphology and quality of life. Anti-VEGF therapy and AI-based fluid analysis will be integrated to explore their impact on disease progression and patient outcomes.","overall_status":"Recruiting","phases":[],"study_type":"OBSERVATIONAL","sponsor":"University of Udine","enrollment":200,"countries":["Italy"],"start_date":"2024-10-01","completion_date":"2029-10-01","last_update_date":"2025-03-27","source_url":"https://clinicaltrials.gov/study/NCT06899360","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"VERA-AMD","age_range":"50 Years to 120 Years","comparator":null,"organization":"University of Udine","interventions":[],"registry_source":"ClinicalTrials.gov","outcome_measures":["Best-corrected visual acuity (BCVA) — through study completion, 36 months","Self-reported vision-targeted quality of life — through study completion, 36 months","Fluid volume (nL) in the retinal compartments — through study completion, 36 months","central retinal thickness — through study completion, 36 months"],"design_description":null,"source_has_results":false},"controlled_terms":["Age-Related Macular Degeneration"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct06899360","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2024-10-01 to 2029-10-01","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years to 120 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.876Z","intervention":[],"participants":200,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Best-corrected visual acuity (BCVA) — through study completion, 36 months","Self-reported vision-targeted quality of life — through study completion, 36 months","Fluid volume (nL) in the retinal compartments — through study completion, 36 months","central retinal thickness — through study completion, 36 months"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41818","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}